Comparison Overview

BioGeneticsRx

VS

Fresenius Kabi Deutschland

BioGeneticsRx

Tampa, US
Last Update: 2025-05-04 (UTC)
Between 800 and 849

At BioGeneticsRx we want positive outcomes for patients + physicians. Using state-of-the-art equipment, our laboratory can process more than 100,000 tests per month. To maximize efficiency, our laboratory is located in Memphis, Tennessee within close proximity to the FedEx hub. Furthermore, Memphis is in the Kahaba Medicare District, which provides favorable reimbursement of most of our PGx tests. State-of-the-art pharmacogeomics testing The ONLY lab with real time analysis tool – CQ Live Platinum quality lab with illumnia DNA testing at the molecular level CLIA and PTan certifications Fast turnaround time Patient receives a QR code card to gain access to CQ Live for PGx results updated real time for life Medicare and Medicaid Approved Most HMO's and PPO's Approved State-of-the-art Medication Reconciliation Tool The CQ Live Medication Reconciliation Tool is the first-ever interactive tool that incorporates drug-to-gene and drug-to-drug interaction. The tool allows physicians to provide personalized care through the CQLive Portal that enhances the existing genetic reports currently on the market. The live portal takes into consideration lifestyle factors, concomitant therapies and genetic markers to ensure patients have the best therapeutic outcome. Every Other PGx Lab only offers a one time Static report. Contact Us Today Toll Free 800-222-5676

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 51-200
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Fresenius Kabi Deutschland

Else-Kröner Straße 1 Bad Homburg, Hesse 61352, DE
Last Update: 2025-03-14 (UTC)

Fresenius Kabi ist ein globales Gesundheitsunternehmen, das seinem Versprechen „Committed to Life“ streng verpflichtet ist. Mit seinen Produkten, Technologien und Dienstleistungen rettet Fresenius Kabi Leben, ermöglicht innovative Therapien und verbessert die Versorgung kritisch und chronisch kranker Patientinnen und Patienten. Über 41.000 Mitarbeitende in rund 100 Ländern setzen sich dafür ein, Menschen Zugang zu hochqualitativen und lebensrettenden Medikamenten und Technologien zu ermöglichen. Im Bereich Biopharma bietet Fresenius Kabi hochmoderne Biosimilars für die Behandlung von Autoimmun- und Krebserkrankungen an. Als einer der weltweit führenden Spezialisten für die klinische Ernährung sorgt Fresenius Kabi mit einem breiten Portfolio an enteralen und parenteralen Produkten für eine optimale Ernährungsversorgung. Im Bereich MedTech werden lebenswichtige Infusionspumpen, Geräte für Zell- und Gentherapien, Einwegprodukte und vieles mehr bereitgestellt. Fresenius Kabi ist außerdem führend in der Ausstattung von Blutzentren und Gesundheitseinrichtungen mit Blutbeutelsystemen und -geräten weltweit. Die hergestellten I.V.-Generika und Infusionslösungen retten jedes Jahr Millionen von Leben – ob in der Notfallmedizin, bei chirurgischen Eingriffen, in der Onkologie oder auf Intensivstationen. Fresenius Kabi verfolgt einen ganzheitlichen Ansatz in der Gesundheitsversorgung mit Kompetenz, Innovation und Engagement – und verbessert damit das Leben von fast 450 Millionen Patientinnen und Patienten jährlich. Basierend auf der Vision 2026 als Teil der #FutureFresenius Strategie entwickelt, produziert und vertreibt Fresenius Kabi kontinuierlich bessere Lösungen. Unser Ziel: unsere Position als führender globaler Therapieanbieter weiter auszubauen, die Patientenversorgung zu optimieren und nachhaltigen Mehrwert zu schaffen. So gestalten wir die Zukunft des Gesundheitswesens aktiv mit. Impressum: https://www.fresenius-kabi.com/de/impressum

NAICS: 325
NAICS Definition:
Employees: 10,001+
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
BioGeneticsRx
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/fresenius-kabi-deutschland-gmbh.jpeg
Fresenius Kabi Deutschland
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
BioGeneticsRx
100%
Compliance Rate
0/4 Standards Verified
Fresenius Kabi Deutschland
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for BioGeneticsRx in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Fresenius Kabi Deutschland in 2025.

Incident History — BioGeneticsRx (X = Date, Y = Severity)

BioGeneticsRx cyber incidents detection timeline including parent company and subsidiaries

Incident History — Fresenius Kabi Deutschland (X = Date, Y = Severity)

Fresenius Kabi Deutschland cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
BioGeneticsRx
Incidents

No Incident

https://images.rankiteo.com/companyimages/fresenius-kabi-deutschland-gmbh.jpeg
Fresenius Kabi Deutschland
Incidents

No Incident

FAQ

BioGeneticsRx company demonstrates a stronger AI Cybersecurity Score compared to Fresenius Kabi Deutschland company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Fresenius Kabi Deutschland company has disclosed a higher number of cyber incidents compared to BioGeneticsRx company.

In the current year, Fresenius Kabi Deutschland company and BioGeneticsRx company have not reported any cyber incidents.

Neither Fresenius Kabi Deutschland company nor BioGeneticsRx company has reported experiencing a ransomware attack publicly.

Neither Fresenius Kabi Deutschland company nor BioGeneticsRx company has reported experiencing a data breach publicly.

Neither Fresenius Kabi Deutschland company nor BioGeneticsRx company has reported experiencing targeted cyberattacks publicly.

Neither BioGeneticsRx company nor Fresenius Kabi Deutschland company has reported experiencing or disclosing vulnerabilities publicly.

Neither BioGeneticsRx nor Fresenius Kabi Deutschland holds any compliance certifications.

Neither company holds any compliance certifications.

Neither BioGeneticsRx company nor Fresenius Kabi Deutschland company has publicly disclosed detailed information about the number of their subsidiaries.

Neither BioGeneticsRx company nor Fresenius Kabi Deutschland company has publicly disclosed the exact number of their employees.

Neither BioGeneticsRx nor Fresenius Kabi Deutschland holds SOC 2 Type 1 certification.

Neither BioGeneticsRx nor Fresenius Kabi Deutschland holds SOC 2 Type 2 certification.

Neither BioGeneticsRx nor Fresenius Kabi Deutschland holds ISO 27001 certification.

Neither BioGeneticsRx nor Fresenius Kabi Deutschland holds PCI DSS certification.

Neither BioGeneticsRx nor Fresenius Kabi Deutschland holds HIPAA certification.

Neither BioGeneticsRx nor Fresenius Kabi Deutschland holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Deck Mate 1 executes firmware directly from an external EEPROM without verifying authenticity or integrity. An attacker with physical access can replace or reflash the EEPROM to run arbitrary code that persists across reboots. Because this design predates modern secure-boot or signed-update mechanisms, affected systems should be physically protected or retired from service. The vendor has not indicated that firmware updates are available for this legacy model.

Risk Information
cvss4
Base: 7.0
Severity: LOW
CVSS:4.0/AV:P/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Deck Mate 2 lacks a verified secure-boot chain and runtime integrity validation for its controller and display modules. Without cryptographic boot verification, an attacker with physical access can modify or replace the bootloader, kernel, or filesystem and gain persistent code execution on reboot. This weakness allows long-term firmware tampering that survives power cycles. The vendor indicates that more recent firmware updates strengthen update-chain integrity and disable physical update ports to mitigate related attack avenues.

Risk Information
cvss4
Base: 7.0
Severity: LOW
CVSS:4.0/AV:P/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Deck Mate 2's firmware update mechanism accepts packages without cryptographic signature verification, encrypts them with a single hard-coded AES key shared across devices, and uses a truncated HMAC for integrity validation. Attackers with access to the update interface - typically via the unit's USB update port - can craft or modify firmware packages to execute arbitrary code as root, allowing persistent compromise of the device's integrity and deck randomization process. Physical or on-premises access remains the most likely attack path, though network-exposed or telemetry-enabled deployments could theoretically allow remote exploitation if misconfigured. The vendor confirmed that firmware updates have been issued to correct these update-chain weaknesses and that USB update access has been disabled on affected units.

Risk Information
cvss4
Base: 7.0
Severity: LOW
CVSS:4.0/AV:P/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Uncontrolled Resource Consumption vulnerability in Legion of the Bouncy Castle Inc. Bouncy Castle for Java FIPS bc-fips on All (API modules), Legion of the Bouncy Castle Inc. Bouncy Castle for Java LTS bcprov-lts8on on All (API modules) allows Excessive Allocation. This vulnerability is associated with program files core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeCFB.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeGCM.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/SHA256NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeEngine.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeCBC.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeCTR.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCFB.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeGCM.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeEngine.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCBC.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeGCMSIV.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCCM.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCTR.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA256NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA224NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA3NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHAKENativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA512NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA384NativeDigest.Java. This issue affects Bouncy Castle for Java FIPS: from 2.1.0 through 2.1.1; Bouncy Castle for Java LTS: from 2.73.0 through 2.73.7.

Risk Information
cvss4
Base: 5.9
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:P/AU:N/R:U/V:C/RE:M/U:Amber
Description

Wasmtime is a runtime for WebAssembly. In versions from 38.0.0 to before 38.0.3, the implementation of component-model related host-to-wasm trampolines in Wasmtime contained a bug where it's possible to carefully craft a component, which when called in a specific way, would crash the host with a segfault or assert failure. Wasmtime 38.0.3 has been released and is patched to fix this issue. There are no workarounds.

Risk Information
cvss4
Base: 2.1
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:P/PR:L/UI:P/VC:N/VI:N/VA:L/SC:N/SI:N/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X